Refined Procedure to Purify and Sequence Circulating Cell-Free DNA in Prostate Cancer
Authors:
- Samira RahimiradSRSamira Rahimirad
- Seta DerderianSDSeta Derderian
- Lucie HamelLHLucie Hamel
- Eleonora ScarlataESEleonora Scarlata
- Ginette McKercherGMGinette McKercher
- Fadi BrimoFBFadi Brimo
- Raghu RajanRRRaghu Rajan
- Alexis Rompre-BrodeurARAlexis Rompre-Brodeur
- Wassim KassoufWKWassim Kassouf
- Rafael Sanchez-SalasRSRafael Sanchez-Salas
- Armen AprikianAAArmen Aprikian
- Simone ChevalierSCSimone Chevalier
Open Access
- 18 June 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (12) , 5839
Abstract
Cell-free DNA (cfDNA), a fragmented DNA circulating in blood, is a promising biomarker for cancer diagnosis and monitoring. Standardization of cfDNA isolation to enhance the sensitivity of molecular analyses in prostate cancer (PCa) is required. Towards this goal, we optimized existing methods to obtain a high quantity and quality of cfDNA from low volumes of plasma. The protocol was applied to samples from healthy males and three patient categories: radical prostatectomy (RP), disease-free (>6 years post-RP), and metastatic castration-resistant PCa (mCRPC). The yield was significantly higher in mCRPC cases, and the size of fragments was shorter. We compared for the first time library preparation using two cfDNA inputs and low vs. high sequencing depth. Clonal events were observed irrespective of input and depth, but lower input showed more subclonal events. The clinical application of the refined protocols to cfDNA samples from an mCRPC patient showed no tumor fraction before RP, while it increased to 25% at the advanced stage. Among chromosomal changes and mutations, the androgen receptor gene amplification was detected. Altogether, this comprehensive study on improved cfDNA procedures is highly promising to enhance the quality of liquid biopsy-based research for discoveries and much-needed clinical applications.Keywords
Funding Information
- Health Canada through the Marathon of Hope Cancer Center Network, under the Terry Fox Research Institute
- CEDAR Cancer Foundation at the McGill University Health Center (MUHC) and PROCURE
This publication has 68 references indexed in Scilit:
- Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic DiseaseEuropean Urology Oncology, 2024
- Whole-body MRI: detecting bone metastases from prostate cancerJapanese Journal of Radiology, 2021
- Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography—The IP1-PROSTAGRAM Study—ReplyJAMA Oncology, 2021
- Advanced ultrasound in the diagnosis of prostate cancerWorld Journal of Urology, 2020
- Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancerEBioMedicine, 2020
- TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate CancerClinical Genitourinary Cancer, 2020
- Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate CancerEuropean Urology, 2019
- Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancerCancer, 2019
- Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression PatternsEuropean Urology, 2017
- Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerJAMA Oncology, 2016